Combined therapy with ezetimibe and rosuvastatin in coronary artery disease patients has similarly resulted in significant reductions in plasma MMP-9 levels, potentially mitigating plaque instability and cardiovascular inflammation [22]. The gene discussed is MMP9; the disease is coronary artery disorder.